👁️

Ophthalmology

22 drugs in pipeline from 9 companies

Drugs in Pipeline

Companies

Upcoming Catalysts

Phase 3 Trials

Upcoming Catalysts

OCULPhase 3$1.1B

✓Positive

OTX-TKI (axitinib implant) Phase 3 Results Expected

OTX-TKI (axitinib implant)• Neovascular Age-Related Macular Degeneration344

Apr 29Estimated

CT.gov

OCULPhase 3$1.1B

✓Positive

Aflibercept Phase 3 Results Expected

Aflibercept• Neovascular Age-related Macular Degeneration344

Apr 29Estimated

CT.gov

ALCPhase 3$11.6B

Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution Phase 3 Results Expected

Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution• Ocular Hypertension489

May 15Estimated

CT.gov

00%

ALCPhase 3$11.6B

Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution Phase 3 Results Expected

AR-17043 Ophthalmic Solution• Open Angle Glaucoma489

May 15Estimated

CT.gov

00%

View all catalysts

Pipeline by Phase

Phase 3

Active Companies

NOVARTIS AG

Roche Holding AG

MERCK

Amgen Inc.

BIO-RAD LABORATORIES, INC.

Novartis AG

Regeneron Pharmaceuticals, Inc.

AbbVie Inc.

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

1 drugs

Related Conditions

eyeretinalmacular degenerationamdglaucomadiabetic retinopathyuveitisdry eyeblindnessvisionophthalmiccorneal